Develop and commercialize diagnostic testing products. Focus on autoimmune and autoimmune-related diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 8% a year on average.
Sales run at $66.6M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $20.0M against $66.6M in annual sales.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, XGN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XGN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.